Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 26 results
Filters: First Letter Of Last Name is P  [Clear All Filters]
Found 26 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

P

Palermo B, Bosch RJ, Bennett K, Jacobson JM. "Body mass index and CD4+ T-lymphocyte recovery in HIV-infected men with viral suppression on antiretroviral therapy." HIV Clin Trials. 2011;12(4):222-7.
Palmer S, Boltz V, Martinson N, et al. "Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission." Proc. Natl. Acad. Sci. U.S.A.. 2006;103(18):7094-9.
Palmer S, Boltz V, Maldarelli F, et al. "Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy." AIDS. 2006;20(5):701-10.
Para MF, Schouten J, Rosenkranz SL, et al. "Phase I/II trial of the anti-HIV activity of mifepristone in HIV-infected subjects ACTG 5200." J. Acquir. Immune Defic. Syndr.. 2010;53(4):491-5.
Paredes R, Lalama CM, Ribaudo HJ, et al. "Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure." J. Infect. Dis.. 2010;201(5):662-71.
Parikh UM, Bacheler L, Koontz D, Mellors JW. "The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations." J. Virol.. 2006;80(10):4971-7.
Paris RM, Petrovas C, Ferrando-Martinez S, et al. "Selective Loss of Early Differentiated, Highly Functional PD1high CD4 T Cells with HIV Progression." PLoS ONE. 2015;10(12):e0144767.
Park YJeong, Etemad B, Ahmed H, et al. "Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption." Pathog Immun. 2017;2(3):431-445.
Parker RA, Rabideau DJ, Sax PE, et al. "Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study." Clin. Infect. Dis.. 2017;64(11):1612-1614.
Parsons TD, Tucker KA, Hall CD, et al. "Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection." AIDS. 2006;20(12):1591-5.
Patterson KB, Cohn SE, Uyanik J, Hughes M, Smurzynski M, Eron JJ. "Treatment responses in antiretroviral treatment-naive premenopausal and postmenopausal HIV-1-infected women: an analysis from AIDS Clinical Trials Group Studies." Clin. Infect. Dis.. 2009;49(3):473-6.
Paul RH, Yiannoutsos CT, Miller EN, et al. "Proton MRS and neuropsychological correlates in AIDS dementia complex: evidence of subcortical specificity." J Neuropsychiatry Clin Neurosci. 2007;19(3):283-92.
Paul RH, Ernst T, Brickman AM, et al. "Relative sensitivity of magnetic resonance spectroscopy and quantitative magnetic resonance imaging to cognitive function among nondemented individuals infected with HIV." J Int Neuropsychol Soc. 2008;14(5):725-33.
Pei L, Hughes MD. "A statistical framework for quantile equivalence clinical trials with application to pharmacokinetic studies that bridge from HIV-infected adults to children." Biometrics. 2008;64(4):1117-25.
Pence BWells, Reif S, Whetten K, et al. "Minorities, the poor, and survivors of abuse: HIV-infected patients in the US deep South." South. Med. J.. 2007;100(11):1114-22.
Pence BWells, Ostermann J, Kumar V, Whetten K, Thielman N, Mugavero MJ. "The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2008;47(2):194-201.
Périssé ARS, Smeaton L, Chen Y, et al. "Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease." PLoS ONE. 2013;8(12):e83643.
Peters MG, Andersen J, Lynch P, et al. "Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127." Hepatology. 2006;44(5):1110-6.
Petersen T, Lee Y-J, Osinusi A, et al. "Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin." AIDS Res. Hum. Retroviruses. 2016;32(7):660-7.
Pillai SK, Pond SLKosakovs, Liu Y, et al. "Genetic attributes of cerebrospinal fluid-derived HIV-1 env." Brain. 2006;129(Pt 7):1872-83.
Podany AT, Bao Y, Swindells S, et al. "Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention." Clin. Infect. Dis.. 2015;61(8):1322-7.
Podany AT, Scarsi KK, Fletcher CV. "Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors." Clin Pharmacokinet. 2017;56(1):25-40.
Pond SLKosakovs, Frost SDW, Grossman Z, Gravenor MB, Richman DD, Brown AJLeigh. "Adaptation to different human populations by HIV-1 revealed by codon-based analyses." PLoS Comput. Biol.. 2006;2(6):e62.
Porter KA, Cole SR, Eron JJ, et al. "HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study." Antimicrob. Agents Chemother.. 2012;56(2):995-1000.
Price P, James I. "IL1A alleles associate with a virological response to antiretroviral therapy in HIV patients beginning therapy with advanced disease." AIDS. 2009;23(9):1173-6.
Putcharoen O, Lee SHee, Henrich TJ, et al. "HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug." J. Virol.. 2012;86(2):1119-28.